Makers Laboratories Ltd
Incorporated in 1984, Makers Laboratories Limited is an integrated pharmaceutical company manufacturing and marketing around 200 formulations. [1]
- Market Cap ₹ 79.8 Cr.
- Current Price ₹ 135
- High / Low ₹ 157 / 98.0
- Stock P/E
- Book Value ₹ 107
- Dividend Yield 0.00 %
- ROCE -1.57 %
- ROE -7.27 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -1.09% over last 3 years.
- Earnings include an other income of Rs.1.53 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 69 | 127 | 101 | 104 | |
| 60 | 108 | 98 | 103 | |
| Operating Profit | 8 | 19 | 3 | 1 |
| OPM % | 12% | 15% | 3% | 1% |
| 1 | 3 | 2 | 2 | |
| Interest | 2 | 2 | 2 | 2 |
| Depreciation | 5 | 4 | 4 | 5 |
| Profit before tax | 3 | 16 | -1 | -4 |
| Tax % | 50% | 25% | -161% | -23% |
| 1 | 12 | -2 | -5 | |
| EPS in Rs | -0.56 | 8.44 | -8.05 | -10.61 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 28% |
| 3 Years: | -9% |
| 1 Year: | 13% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -1% |
| Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Equity Capital | 5 | 5 | 6 | 6 |
| Reserves | 49 | 55 | 63 | 57 |
| 21 | 23 | 17 | 19 | |
| 62 | 62 | 66 | 79 | |
| Total Liabilities | 136 | 144 | 152 | 161 |
| 71 | 68 | 85 | 87 | |
| CWIP | 0 | 9 | 0 | 0 |
| Investments | 2 | 0 | 0 | 3 |
| 63 | 66 | 67 | 71 | |
| Total Assets | 136 | 144 | 152 | 161 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 0 | 18 | -9 | 1 | |
| 0 | -22 | 1 | -7 | |
| 0 | 0 | 6 | 6 | |
| Net Cash Flow | 0 | -3 | -2 | -0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 88 | 39 | 72 | 70 |
| Inventory Days | 344 | 166 | 281 | 227 |
| Days Payable | 182 | 38 | 91 | 126 |
| Cash Conversion Cycle | 250 | 167 | 262 | 170 |
| Working Capital Days | 159 | 104 | 140 | 137 |
| ROCE % | 15% | 1% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 1h
- Closure of Trading Window 21 Jun
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
28 May - Compliance Report for the year ended 31st March 2024
- Announcement under Regulation 30 (LODR)-Newspaper Publication 25 May
- Proposed Sale Of Land And Office Building 23 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio
The Co’s product portfolio covers a wide range of General Health Therapeutic segments. Its top formulation brands are Duramol (Paracetamol), Artemak-AB (a-ß Arteether), Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti-Cough range) and Exylin (Amoxycillin range). [1]